Logo image of NUMI.CA

NUMINUS WELLNESS INC (NUMI.CA) Stock Fundamental Analysis

TSX:NUMI - Toronto Stock Exchange - CA67054W1032 - Common Stock - Currency: CAD

0.05  +0.02 (+42.86%)

Fundamental Rating

3

Taking everything into account, NUMI scores 3 out of 10 in our fundamental rating. NUMI was compared to 34 industry peers in the Pharmaceuticals industry. NUMI has a bad profitability rating. Also its financial health evaluation is rather negative. NUMI shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NUMI had negative earnings in the past year.
In the past year NUMI has reported a negative cash flow from operations.
NUMI had negative earnings in each of the past 5 years.
In the past 5 years NUMI always reported negative operating cash flow.
NUMI.CA Yearly Net Income VS EBIT VS OCF VS FCFNUMI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

NUMI's Return On Assets of -213.24% is on the low side compared to the rest of the industry. NUMI is outperformed by 90.91% of its industry peers.
Looking at the Return On Equity, with a value of -644.74%, NUMI is doing worse than 81.82% of the companies in the same industry.
Industry RankSector Rank
ROA -213.24%
ROE -644.74%
ROIC N/A
ROA(3y)-79.64%
ROA(5y)-255.28%
ROE(3y)-118.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NUMI.CA Yearly ROA, ROE, ROICNUMI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

With a Gross Margin value of 32.02%, NUMI perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
NUMI's Gross Margin has improved in the last couple of years.
NUMI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.27%
GM growth 5YN/A
NUMI.CA Yearly Profit, Operating, Gross MarginsNUMI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

NUMI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NUMI has been increased compared to 1 year ago.
The number of shares outstanding for NUMI has been increased compared to 5 years ago.
Compared to 1 year ago, NUMI has a worse debt to assets ratio.
NUMI.CA Yearly Shares OutstandingNUMI.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
NUMI.CA Yearly Total Debt VS Total AssetsNUMI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

NUMI has an Altman-Z score of -13.73. This is a bad value and indicates that NUMI is not financially healthy and even has some risk of bankruptcy.
NUMI's Altman-Z score of -13.73 is on the low side compared to the rest of the industry. NUMI is outperformed by 81.82% of its industry peers.
A Debt/Equity ratio of 0.95 indicates that NUMI is somewhat dependend on debt financing.
The Debt to Equity ratio of NUMI (0.95) is worse than 78.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF N/A
Altman-Z -13.73
ROIC/WACCN/A
WACC8.99%
NUMI.CA Yearly LT Debt VS Equity VS FCFNUMI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.40 indicates that NUMI should not have too much problems paying its short term obligations.
NUMI has a Current ratio (1.40) which is comparable to the rest of the industry.
NUMI has a Quick Ratio of 1.40. This is a normal value and indicates that NUMI is financially healthy and should not expect problems in meeting its short term obligations.
NUMI has a better Quick ratio (1.40) than 60.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
NUMI.CA Yearly Current Assets VS Current LiabilitesNUMI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

NUMI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.67%, which is quite impressive.
The Revenue has grown by 22.69% in the past year. This is a very strong growth!
NUMI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 197.54% yearly.
EPS 1Y (TTM)37.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.87%
Revenue 1Y (TTM)22.69%
Revenue growth 3Y197.54%
Revenue growth 5YN/A
Sales Q2Q%-27.88%

3.2 Future

NUMI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.53% yearly.
Based on estimates for the next years, NUMI will show a very strong growth in Revenue. The Revenue will grow by 22.63% on average per year.
EPS Next Y58.33%
EPS Next 2Y38.44%
EPS Next 3Y25.99%
EPS Next 5Y29.53%
Revenue Next Year-18.04%
Revenue Next 2Y-0.45%
Revenue Next 3Y11.96%
Revenue Next 5Y22.63%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NUMI.CA Yearly Revenue VS EstimatesNUMI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
NUMI.CA Yearly EPS VS EstimatesNUMI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NUMI. In the last year negative earnings were reported.
Also next year NUMI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUMI.CA Price Earnings VS Forward Price EarningsNUMI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUMI.CA Per share dataNUMI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1

4.3 Compensation for Growth

A more expensive valuation may be justified as NUMI's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.44%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

NUMI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUMINUS WELLNESS INC

TSX:NUMI (1/29/2025, 7:00:00 PM)

0.05

+0.02 (+42.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-13 2025-01-13
Earnings (Next)N/A N/A
Inst Owners2.66%
Inst Owner ChangeN/A
Ins Owners3.55%
Ins Owner ChangeN/A
Market Cap16.12M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.62
P/FCF N/A
P/OCF N/A
P/B 3.48
P/tB 3.48
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.08
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -213.24%
ROE -644.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.02%
FCFM N/A
ROA(3y)-79.64%
ROA(5y)-255.28%
ROE(3y)-118.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.27%
GM growth 5YN/A
F-Score2
Asset Turnover1.86
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.51%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z -13.73
F-Score2
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)61.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)21.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.87%
EPS Next Y58.33%
EPS Next 2Y38.44%
EPS Next 3Y25.99%
EPS Next 5Y29.53%
Revenue 1Y (TTM)22.69%
Revenue growth 3Y197.54%
Revenue growth 5YN/A
Sales Q2Q%-27.88%
Revenue Next Year-18.04%
Revenue Next 2Y-0.45%
Revenue Next 3Y11.96%
Revenue Next 5Y22.63%
EBIT growth 1Y24.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.26%
OCF growth 3YN/A
OCF growth 5YN/A